The results of a phase 2b ENLIVEN trial of FGF21 analogue pegozafermin showed it was able to reduce scarring (fibrosis) in the liver of NASH patients at more than three times the rate of a placebo ...

Novartis has joined with Allergan in a bid to get ahead in the race to get a drug approved to treat the fatty liver disease, non-alcoholic steatohepatitis (NASH). The Swiss pharma said it is to ...

Recently, former Mavericks and Lakers guard Steve Nash shared his candid initial reaction to the deal, per Josh Donaldson of Flashscore. “Yeah, I think everybody was shocked. They clearly did an ...

2024 at 8:20 AM ET and participate in one-on-one investor me New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which ...

After hours: March 11 at 6:15:15 PM EDT Loading Chart for ETNB ...

Aanika Warner says American education and how our kids learn needs a reboot.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe ...

Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe ...